Literature DB >> 30956093

Potential antitumour activity of pasireotide on pituitary tumours in acromegaly.

Eva C Coopmans1, Aart J van der Lely2, Joppe J Schneiders3, Sebastian J C M M Neggers2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30956093     DOI： 10.1016/S2213-8587(19)30113-5

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  7 in total

1.  Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study.

Authors:  Hélène Lasolle; Amandine Ferriere; Alexandre Vasiljevic; Sandrine Eimer; Marie-Laure Nunes; Antoine Tabarin
Journal:  Endocr Connect       Date:  2019-10       Impact factor: 3.335

2.  Risk factors and management of pasireotide-associated hyperglycemia in acromegaly.

Authors:  Mônica R Gadelha; Feng Gu; Marcello D Bronstein; Thierry C Brue; Maria Fleseriu; Ilan Shimon; Aart J van der Lely; Shoba Ravichandran; Albert Kandra; Alberto M Pedroncelli; Annamaria A L Colao
Journal:  Endocr Connect       Date:  2020-12       Impact factor: 3.335

Review 3.  The Future of Somatostatin Receptor Ligands in Acromegaly.

Authors:  Monica R Gadelha; Luiz Eduardo Wildemberg; Leandro Kasuki
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

4.  Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis.

Authors:  Alessandro Mondin; Renzo Manara; Giacomo Voltan; Irene Tizianel; Luca Denaro; Marco Ferrari; Mattia Barbot; Carla Scaroni; Filippo Ceccato
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-01       Impact factor: 6.055

5.  Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.

Authors:  Agnieszka Tomasik; Maria Stelmachowska-Banaś; Maria Maksymowicz; Izabella Czajka-Oraniec; Dorota Raczkiewicz; Grzegorz Zieliński; Jacek Kunicki; Wojciech Zgliczyński
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-16       Impact factor: 6.055

Review 6.  Pasireotide in the Personalized Treatment of Acromegaly.

Authors:  Manel Puig-Domingo; Ignacio Bernabéu; Antonio Picó; Betina Biagetti; Joan Gil; Cristina Alvarez-Escolá; Mireia Jordà; Montserrat Marques-Pamies; Berta Soldevila; María-Angeles Gálvez; Rosa Cámara; Javier Aller; Cristina Lamas; Mónica Marazuela
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555

Review 7.  Pasireotide-a novel somatostatin receptor ligand after 20 years of use.

Authors:  Marek Bolanowski; Marcin Kałużny; Przemysław Witek; Aleksandra Jawiarczyk-Przybyłowska
Journal:  Rev Endocr Metab Disord       Date:  2022-01-24       Impact factor: 9.306
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.